NCT05157100

Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia

Prospective, Open-label Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: The Orthopedic Foundation · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

Study of Ingrezza (Valbenazine) for the treatment of cervical dystonia.

Detailed description

The study will be an open-label, prospective study. Patients with a diagnosis of cervical dystonia will undergo 4 weeks of baseline evaluation, followed by a 12-week treatment period. Subjects will be evaluated in-clinic every 4 weeks. Standardized assessments will be performed at these visits. Data will also be collected from wearable IMUs (inertial measurement units) and analyzed for improvements in involuntary, repetitive movements and postures.

Conditions

• Cervical Dystonia

Interventions

Type	Name	Description
DRUG	Ingrezza Pill	Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.

Timeline

• Start date: 2021-10-19
• Primary completion: 2023-09-15
• Completion: 2023-09-15
• First posted: 2021-12-14
• Last updated: 2023-10-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study